Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).-MedSci.cn

Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).

Strowd, RE; Ellingson, BM; Wen, PY; Ahluwalia, MS; Piotrowski, AF; Desai, AS; Clarke, JL; Lieberman, FS; Desideri, S; Nabors, LB; Ye, XB; Grossman, SA

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务